125 related articles for article (PubMed ID: 31274231)
21. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
Chianese-Bullock KA; Irvin WP; Petroni GR; Murphy C; Smolkin M; Olson WC; Coleman E; Boerner SA; Nail CJ; Neese PY; Yuan A; Hogan KT; Slingluff CL
J Immunother; 2008 May; 31(4):420-30. PubMed ID: 18391753
[TBL] [Abstract][Full Text] [Related]
22. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.
Hueman MT; Dehqanzada ZA; Novak TE; Gurney JM; Woll MM; Ryan GB; Storrer CE; Fisher C; McLeod DG; Ioannides CG; Ponniah S; Peoples GE
Clin Cancer Res; 2005 Oct; 11(20):7470-9. PubMed ID: 16243821
[TBL] [Abstract][Full Text] [Related]
23. Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design.
Jackson DO; Trappey FA; Clifton GT; Vreeland TJ; Peace KM; Hale DF; Litton JK; Murray JL; Perez SA; Papamichail M; Mittendorf EA; Peoples GE
Clin Immunol; 2018 Oct; 195():28-35. PubMed ID: 30025819
[TBL] [Abstract][Full Text] [Related]
24. Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides.
Peoples GE; Anderson BW; Fisk B; Kudelka AP; Wharton JT; Ioannides CG
Ann Surg Oncol; 1998 Dec; 5(8):743-50. PubMed ID: 9869522
[TBL] [Abstract][Full Text] [Related]
25. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
Knutson KL; Schiffman K; Cheever MA; Disis ML
Clin Cancer Res; 2002 May; 8(5):1014-8. PubMed ID: 12006513
[TBL] [Abstract][Full Text] [Related]
26. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
[TBL] [Abstract][Full Text] [Related]
27. Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial.
Patil R; Clifton GT; Holmes JP; Amin A; Carmichael MG; Gates JD; Benavides LH; Hueman MT; Ponniah S; Peoples GE
J Am Coll Surg; 2010 Feb; 210(2):140-7. PubMed ID: 20113933
[TBL] [Abstract][Full Text] [Related]
28. Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients.
Kalli KR; Block MS; Kasi PM; Erskine CL; Hobday TJ; Dietz A; Padley D; Gustafson MP; Shreeder B; Puglisi-Knutson D; Visscher DW; Mangskau TK; Wilson G; Knutson KL
Clin Cancer Res; 2018 Jul; 24(13):3014-3025. PubMed ID: 29545464
[No Abstract] [Full Text] [Related]
29. The comparison of cytotoxic T-lymphocyte effects of dendritic cells stimulated by the folate binding protein peptide cultured with IL-15 and IL-2 in solid tumor.
Kim DK; Kim JH; Kim YT; Kim JW; Ioannides CG
Yonsei Med J; 2002 Dec; 43(6):691-700. PubMed ID: 12497651
[TBL] [Abstract][Full Text] [Related]
30. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
Slingluff CL; Petroni GR; Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Hibbitts S; Teates D; Neese PY; Grosh WW; Chianese-Bullock KA; Woodson EM; Wiernasz CJ; Merrill P; Gibson J; Ross M; Engelhard VH
J Clin Oncol; 2003 Nov; 21(21):4016-26. PubMed ID: 14581425
[TBL] [Abstract][Full Text] [Related]
31. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Peoples GE; Holmes JP; Hueman MT; Mittendorf EA; Amin A; Khoo S; Dehqanzada ZA; Gurney JM; Woll MM; Ryan GB; Storrer CE; Craig D; Ioannides CG; Ponniah S
Clin Cancer Res; 2008 Feb; 14(3):797-803. PubMed ID: 18245541
[TBL] [Abstract][Full Text] [Related]
32. Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients.
Kim DK; Lee TV; Castilleja A; Anderson BW; Peoples GE; Kudelka AP; Murray JL; Sittisomwong T; Wharton JT; Kim JW; Ioannides CG
Anticancer Res; 1999; 19(4B):2907-16. PubMed ID: 10652572
[TBL] [Abstract][Full Text] [Related]
33. Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer.
Chick RC; Clifton GT; Hale DF; Vreeland TJ; Hickerson AT; Kemp Bohan PM; McCarthy PM; Litton JK; Alatrash G; Murthy RK; Qiao N; Philips A; Lukas J; Holmes JP; Mittendorf EA; Peoples GE
Clin Immunol; 2021 Apr; 225():108679. PubMed ID: 33485895
[TBL] [Abstract][Full Text] [Related]
34. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
Chianese-Bullock KA; Pressley J; Garbee C; Hibbitts S; Murphy C; Yamshchikov G; Petroni GR; Bissonette EA; Neese PY; Grosh WW; Merrill P; Fink R; Woodson EM; Wiernasz CJ; Patterson JW; Slingluff CL
J Immunol; 2005 Mar; 174(5):3080-6. PubMed ID: 15728523
[TBL] [Abstract][Full Text] [Related]
35. Continuous low-dose GM-CSF as salvage therapy in refractory recurrent breast or female genital tract carcinoma.
Kurbacher CM; Kurbacher JA; Cramer EM; Rhiem K; Mallman PK; Reichelt R; Reinhold U; Stier U; Cree IA
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 2):23-6. PubMed ID: 15934497
[TBL] [Abstract][Full Text] [Related]
36. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
[TBL] [Abstract][Full Text] [Related]
37. Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial.
Shimizu Y; Yoshikawa T; Kojima T; Shoda K; Nosaka K; Mizuno S; Wada S; Fujimoto Y; Sasada T; Kohashi K; Bando H; Endo I; Nakatsura T
Cancer Sci; 2019 Oct; 110(10):3049-3060. PubMed ID: 31390678
[TBL] [Abstract][Full Text] [Related]
38. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer.
Feyerabend S; Stevanovic S; Gouttefangeas C; Wernet D; Hennenlotter J; Bedke J; Dietz K; Pascolo S; Kuczyk M; Rammensee HG; Stenzl A
Prostate; 2009 Jun; 69(9):917-27. PubMed ID: 19267352
[TBL] [Abstract][Full Text] [Related]
39. A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors.
Hung CF; Calizo R; Tsai YC; He L; Wu TC
Vaccine; 2007 Jan; 25(1):127-35. PubMed ID: 16930783
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial.
Mittendorf EA; Lu B; Melisko M; Price Hiller J; Bondarenko I; Brunt AM; Sergii G; Petrakova K; Peoples GE
Clin Cancer Res; 2019 Jul; 25(14):4248-4254. PubMed ID: 31036542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]